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Seroprevalence and HIV-associated factors among adults 
with severe mental illness – a vulnerable population
Dinesh Singh, Alan Berkman, Michaeline Bresnahan
HIV is associated with major psychiatric disorders (also termed 
severe mental illness (SMI)), including major depression 
and bipolar and psychotic disorders.1,2 Adults with SMI 
have a 2 - 36 times higher seroprevalence of HIV than the 
general population,3-6 and HIV-infected people have a higher 
prevalence of SMI.7 A systematic review concluded: ‘… adults 
with SMI are at high risk for HIV/STD’.8 In their review, Joska 
et al. recommended provider-initiated testing and counselling 
(PITC) for adults with SMI.9 The World Health Organization 
(WHO) recommends PITC in generalised epidemics and 
prioritises implementation in vulnerable groups (e.g. medical 
inpatients10), but adults with SMI are not explicitly identified. 
PITC can be implemented subject to the following: informed 
consent, the right to refuse, the availability of counselling, 
follow-up, and antiretroviral (ARV) treatment.10 PITC has 
drawn much criticism;11 its prerequisites cannot be assured 
in patients with SMI. The Mental Health Care Act (MHCA) 
allows medical superintendents to approve HIV testing. 
There is limited evidence from South Africa to recommend 
policy changes that have serious ethical and public health 
implications. We studied whether adults with SMI can be 
considered as a vulnerable population.
The recommendation for PITC is based on evidence 
mainly from cross-sectional studies in the developed world 
on the prevalence of SMI among HIV-infected people or 
seroprevalence among those with SMI.9 The strength of 
association between HIV and mental illness varies according 
to the presence of other risk factors in these different 
populations. There are risk factors (e.g. substance abuse) 
common to HIV, and psychiatric disorders that may act as 
mediators, moderators, proxies, confounders or overlapping 
risk factors. There are also conceptual reservations about 
how these risk factors work together and whether statistical 
tests can fully adjust for these effects.12 The increased HIV 
prevalence in patients with SMI may be overestimated because 
studies included high-risk groups such as the homeless and 
intravenous drug users, and the treatment setting varied, with 
inpatient, outpatient and forensic units. Himelhoch et al. found 
that the elevated prevalence of HIV among those with SMI is 
due to the HIV-related risk factors that underlie the association 
between HIV and SMI,13 viz. age <39 years, male, African-
American, Latino, schizophrenia, dual diagnosis, and high-risk 
behaviour (prostitution, sex with parenteral drug-taker, male-
male sex, drug injection).7 Mentally ill patients with HIV in the 
developed world have multiple HIV risk factors that account 
for the increased prevalence of HIV.
Despite more than 68% of the world’s HIV burden being in 
sub-Saharan Africa,14 few studies from the region describe the 
seroprevalence of HIV among the mentally ill.9,15-17 Our study 
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Background. Adults with severe mental illness (SMI) display 
an increased prevalence of HIV compared with the general 
population. Recommendations for provider-initiated testing 
in South Africa lack robust evidence because the studies – 
mainly from low-prevalence regions – overestimate the risk of 
HIV among adults with SMI.
Objective. We aimed to assess whether the mentally ill are a 
vulnerable population in South Africa.
Methods. All new admissions to an acute psychiatric 
ward from July to December 2000 were tested for HIV 
anonymously and the results linked with socio-demographic 
and clinical data. We did a restricted analysis of black females 
from a population-based survey of black females with SMI.
Results. There were 216 admissions, of whom 206 were 
included in the analysis. The seroprevalence of HIV-1 was 
29.1% (confidence interval 27.8 - 32.4); seroprevalence of HIV 
among the women was 40%. The following predicted HIV 
positivity: female (odds ratio (OR) 3.5 (1.7 - 6.9)), infections 
of the chest or central nervous system (OR 3.2 (1.4 - 7.5)), 
age group 30 - 39 years (OR 2.3 (1.1 - 4.8)) and aggression on 
admission. The age and sex ratios among the SMI group were 
similar to the general population. Adults with SMI have an 
almost three times greater prevalence of HIV than the general 
population, after controlling for age and gender.
Conclusions. Adults with SMI are a vulnerable population; 
therefore, provider-initiated HIV testing and other prevention 
and treatment programmes must be tailored to their needs.
S Afr Med J 2009; 99: 523-527.
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describes the seroprevalence of HIV in an acute psychiatric 
ward in South Africa, which has a generalised epidemic. In a 
region with a generalised epidemic, HIV is firmly established 
and can be sustained by sexual networking alone. Therefore, 
people with HIV may not have multiple risk factors for HIV. 
This state contrasts with the multiple risk factors for HIV 
among those with SMI, as described in low-prevalence regions. 
We may obtain a more valid assessment of the association 
between HIV and SMI because there are fewer statistical 
adjustments and the unknown effect of multiple overlapping 
risk factors is not applicable. We compared HIV seroprevalence 
in the SMI group with the general population; if higher, this 
group should be considered to be a vulnerable population. If 
adults with SMI are a vulnerable population, it would partly 
counter the arguments against PITC11 and support special HIV 
prevention and treatment programmes targeted at this group.
Methods
We undertook a descriptive study from 1 July to 31 December 
2000 in the in-patient psychiatric ward at King Edward VIII 
Hospital (KEH), a public sector hospital affiliated with the 
Nelson R Mandela School of Medicine in Durban, KwaZulu-
Natal (KZN). KZN has a population of over 9.5 million people of 
whom only about 9% have private health insurance. The HIV 
seroprevalence among 15 - 49-year-olds in KZN was 15.7% in 
2002.18 This figure has since increased; it is estimated that, in 
2008, 5.7 million South Africans were HIV infected.
Patients are referred to the KEH psychiatric department from 
outlying community clinics and other hospital departments. 
The psychiatric ward is a 20-bed acute psychiatric unit for 
males and females; only those with SMI are admitted, and 
only medically stable patients are admitted to the psychiatric 
ward as those with serious medical conditions are managed in 
the medical wards. All patients admitted to this ward during 
this period were tested for HIV using the enzyme-linked 
immunosorbent assay (ELISA) and Western blot tests. The 
attending clinician completed a questionnaire to collect data on 
age, sex, medical history, substance abuse in the last 3 months, 
physical findings, duration of hospital stay, and final diagnosis, 
which were linked with HIV test results for the analysis.
There were 216 admissions, and no patient was counted 
twice; 8 with incomplete clinical data or missing sero-status, 
and 2 with equivocal test results, were excluded. We present 
the data from more than 95% of all admissions from the study 
period.
The Nelson R Mandela School of Medicine Bioethics 
Research Ethics Committee and the Columbia University 
Institutional Review Board (IRB) approved this study.
HIV infection status
Discarded blood taken for routine chemistry as part of 
baseline investigations was tested for HIV by the ELISA test. 
All identifiers, except a unique 6-digit number assigned for 
the purpose of the study, were removed. Reactive samples 
were confirmed with the Western blot test and classified as 
recommended by the Centers for Disease Control. A specimen 
was considered positive if antibodies to two of the following 
were detected: p24, gp41 and gp120/160. The presence 
of a single band on the Western blot was considered an 
indeterminate result. Retesting when results were inconclusive 
was impossible as testing was anonymous.
Data analysis
Psychosis was defined as the presence of two or more of the 
following: hallucinations, delusions, abnormal behaviour (e.g. 
removing clothes, aggression) or formal thought disorder. 
Aggression was assessed from historical data and clinical 
assessment.
Substance abuse was defined as a pattern of use that caused 
clinically significant distress or impairment. The type of 
substance was specified.
Examples of medical co-morbidity are pulmonary 
tuberculosis and meningitis, and chronic disorders included 
hypertension and asthma. Patients with delirium and unstable 
medical co-morbidities were managed in the medical wards, or 
their conditions were stabilised before they were transferred to 
the psychiatric ward.
Age and duration of hospital stay were measured 
continuously. The distributions were checked for normality and 
log transformed. Age was divided into categories commonly 
presented in other HIV epidemiological surveys.18
Methods of analysis
Descriptive statistics were used to describe the study 
population. To determine significant differences, t-tests, chi-
squared and Fisher’s exact tests were used. Odds ratios (ORs) 
were used to evaluate the association between each covariate 
and the outcome. Results were considered statistically 
significant where p<0.05. We compared our data with a valid 
estimate of HIV seroprevalence in the general population 
of South Africa. The Nelson Mandela/Human Sciences 
Research Council (HSRC) study of HIV/AIDS was a national, 
population-based survey that included a representative sample 
of more than 9 900 people from all provinces, localities and 
races.18,19 Data for this study were collected a year after our 
study was completed. Therefore, we have a valid estimate 
of the seroprevalence of HIV in the general population in 
the year 2000. We obtained the sample size in specific age, 
race and gender categories, and did a restricted analysis 
of the HIV-positive women in our study. To adjust for the 
confounding effects caused by the differing age structure of 
our study population, we standardised age-specific and overall 
prevalence.
Differences between HIV-positive and negative admissions 
on various characteristics were assessed using Pearson chi-
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squared tests (categorical data) and t-tests (continuous data). 
Variables that were statistically significant in the univariate 
analysis were entered into a stepwise multivariate logistic 
regression model to predict HIV status. To distinguish acute 
diseases from chronic medical disorders, infections of the 
central nervous system (e.g. meningitis) and chest (e.g. 
pulmonary tuberculosis) were collapsed into one category. ORs 
and 95% confidence intervals (CIs) are provided. Data were 
analysed using the Statistical Package for the Social Sciences 
(SPSS), version 16.0.
Results
Overall seroprevalence of HIV and socio-
demographic characteristics of HIV-positive and 
HIV-negative patients
A complete set of confirmed HIV results and clinical records 
were available for 206 patients. The overall prevalence of 
HIV was 29.1% (CI 27.8 - 32.4% – Table I). Women had an 
approximately twofold increase in seroprevalence compared 
with men (female:male ratio = 2.1:1). The majority of patients 
were <30 years old, and no HIV-positive patient was >50 
years. All patients had SMI and most were psychotic. The 
spectrum of substance abuse was limited and did not include 
intravenous drugs. Cannabis was the most common drug. A 
higher proportion of HIV-negative than HIV-positive patients 
took cannabis (p=0.007).
The prevalence of HIV among black women aged 15 - 49 
years in the general population in South Africa was 20.7%.18 
The prevalence of HIV among the women in this study was 
40.1% (36/88). To control for the confounding effects of gender 
and age, we standardised the age and did a restricted analysis 
of the women in our study (all black) and the black women 
in the HSRC study (Fig. 1). Black women with SMI had a 
consistently higher prevalence of HIV in each age category. The 
difference was largest (3.6 times) in the 35 - 39-year age group.
Multiple logistic regression analysis confirmed that socio-
demographic characteristics (female and age group 30 - 39 
years) and certain clinical characteristics (aggression and 
meningitis or tuberculosis) were independently associated with 
HIV (Table II). The adjusted OR showed that women have a 3.5 
times greater probability of being HIV positive than men.
Discussion
The overall prevalence of HIV among adults with SMI was 
29.1% (CI 27.8 - 32.4). This was almost three times higher than 
that of the general population. The seroprevalence among 
black women in our study was 40%. HIV seroprevalence was 
higher among mentally ill women than women in the general 
population across all age categories. Socio-demographic 
characteristics (age and sex) and known clinical characteristics 
(past or current infections, e.g. meningitis and pulmonary TB) 
were more predictive of HIV status than psychiatric symptoms 
(aggression). There were no cases of intravenous drug use.
The seroprevalence of HIV in our study was higher than in 
all other published studies of adults with SMI, notwithstanding 
the differences of study populations and HIV testing  
methods.3-6,15-17,20-22 To assess if adults with SMI have a higher 
HIV seroprevalence than the general population, a valid 
estimate of the HIV seroprevalence in the general population 
must be used. There is marked heterogeneity of HIV, even 
within a country;18 HIV varies by race, sex and age.18 Antenatal 
surveys only include sexually active, fertile, pregnant females 
from a limited age category, and who are therefore unsuitable 
for estimating the prevalence of HIV in the general population. 
Population-based surveys, of which the HSRC study is the 
Table I. Socio-demographic, clinical and psychiatric 
characteristics of patients in a ward, 2000
          HIV positive   HIV negative
               (N=60)      (N=146)         p-value
Female (%)     60           36               0.001
Age (yrs) (%)  30.2         30.6
15 - 29      50           58 
30 - 39      37           20               0.02
40 - 49      13           12 
≥50        0           10 
Black (%)    100         100 
Substance abuse (%)   
Cannabis     18           38               0.007
Alcohol     12           15 
Mandrax    1.5          0.5 
Glue     1.5          0.5 
Physical findings (%)
Normal     60           77 
Chest infections      13             2               0.001
(pulmonary TB, pneumonia)
CNS infections      13             8               0.04
(e.g. cryptococcal meningitis)
Chronic disorders       8             8 
(e.g. hypertension, asthma)
Symptoms   
Hallucinations –      65           63 
any type (%)
Auditory only     37            41 
Visual only       2           14               0.009
Auditory and visual    25             8 
Auditory and tactile      2             1 
Mood symptoms: any (%)    40           29 
Depressive symptoms    18           12 
Manic symptoms     22           17 
Formal thought      10           15 
disorder (%)
Abnormal behaviour (%)    67           74 
Aggression (%)     52           43 
Delusions (any type) (%)    48           54 
Psychosis (%)     90           90 
Total stay in hospital (days) 10.8           14               0.05
CNS = central nervous system.
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latest,18,19 provide a more valid estimate of the prevalence of 
HIV in the general population. In 2002, the overall prevalence 
of HIV in South Africa was 11.4%.18
HIV is a female-predominant epidemic in sub-Saharan 
Africa. In South Africa, women between the ages of 15 and 
24 years were four times more likely to acquire HIV than 
men (16.9% v. 4.4%).18 In our study, the overall and gender-
specific HIV seroprevalence was higher than that of the general 
population. Adults with SMI have a higher prevalence of HIV 
than the general population, even after considering racial, 
gender and age differences.
Compared with the general population, there was an almost 
tripled increase of HIV in adults with SMI (11.4% v. 29.1%). 
The prevalence of HIV in anonymous linked studies that were 
conducted in low-prevalence regions vary from 1% to 7%,22,23 
which is 2 - 12 times higher than the prevalence of HIV in 
the general population. This difference is greater in studies 
that included patients with common risk factors for HIV and 
mental illness.6-8 The joint risk of acquiring HIV from other 
high-risk behaviours that accompany mental and co-morbid 
disorders (e.g. substance abuse) may account for the increased 
seroprevalence among the mentally ill compared with the 
general population. An HIV seroprevalence of 19.4% was 
reported in adults with SMI who were homeless and had high 
levels of alcohol abuse.6 Schizophrenics without substance 
abuse were found to have a lower risk for HIV.13 In this study, 
the prevalence of substance abuse (mainly cannabis) among the 
HIV-positive patients was low.
HIV-positive patients with SMI in low-prevalence regions 
have multiple risk factors for HIV.7,8 The age and sex ratios of 
the HIV-positive patients in our study were similar to those 
of the HIV-positive patients in the general population.18 The 
multivariate analysis confirms that age and sex are associated 
with HIV seropositivity, which suggests that the same factors 
driving the epidemic regionally are responsible for the 
high HIV prevalence among the mentally ill. However, the 
remaining excess seroprevalence of HIV suggests an increased 
risk to the mentally ill for contracting HIV. This claim is 
made cautiously as cross-sectional studies cannot establish 
causality, and our study was not designed to examine the 
nature of the association. Others have reported that patients 
with schizophrenia and SMI have poor HIV/AIDS knowledge, 
cognitive deficits, affective instability, behavioural impulsivity, 
and high rates of HIV risk-behaviour, which all contribute to 
HIV acquisition. In summary, the seroprevalence of HIV among 
those with SMI appears to be a function of their risk networks. 
In low-prevalence regions, those with SMI have multiple risk 
factors for HIV, including sexual and drug-related behaviours. 
However, in a generalised epidemic, sexual contact is the main 
mode of transmission.
After considering possible biases that might have been 
introduced through methodological and statistical differences, 
we conclude that the severely mentally ill is a vulnerable 
population, and we recommend provider-initiated testing 
and counselling. Public health benefits must not undermine 
the human rights of patients with SMI; PITC may increase 
stigma, the right to autonomy must be respected, and those 
with SMI may often not be able to decline testing or give 
informed consent. PITC must not be implemented in a 
vacuum; confidentiality, post-test counselling when patients 
can assimilate information, and access to ARVs and ongoing 
HIV care must be assured.
Our study has the following strengths: We have a 
valid estimate of the seroprevalence of HIV. As a result 
of anonymous testing, we included more than 95% of all 
admissions for the study period, which increased the power 
and reduced selection bias. The seroprevalence of HIV ranged 


















Fig. 1. Comparison of the prevalence of HIV among African
women in the general population and African women with


















Fig. 1. Comparison of the prevalence of HIV among African
women in the general population and African women with
severe mental illness after standardising for age.
Fig. 1. Comparison of the prevalence of HIV among black women in the 
general population and black women with severe mental illness after 
standardising for age.
Table II. Multiple logistic regression to determine 
predictors of HIV seropositivity
Variable  OR           95% CI           p-value
Male  1.0
Female  3.45         1.73 - 6.91             0.000
Normal  1.0
Infections in the 3.22         1.38 - 7.51             0.007
CNS or chest
Age 15 - 29 yrs 1.0
Age 30 - 39 yrs 2.31         1.13 - 4.75             0.022
No aggression 1.0
Aggression 2.11         1.05 - 4.21             0.035
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for HIV,20,21 and from 0% to 28% in studies with voluntary 
testing.4,5,21 Anonymous testing is more accurate because it 
includes patients who may otherwise not consent to HIV 
testing, or patients incapable of giving informed consent. 
Studies with informed consent may self-select patients who 
suspect they may be HIV-positive. Almost all our patients were 
psychotic on admission and might have been unable to consent 
to HIV testing. Ethical problems with anonymous testing 
include the consideration that it would be considered unethical 
to test an individual and not disclose the result if effective 
treatment is available. At the time of this study (2000), no ARV 
therapy was available in the public sector in South Africa. 
It is unlikely that another, similar study would be approved 
by any IRB, and future studies will have selection bias. We 
acknowledge that the data were collected in 2000 but, given the 
ethical considerations of anonymous testing and easier access 
to ARVs, it is unlikely this study design will be replicated. We 
had a valid estimate of HIV among the general population at 
the time of our study.
Our findings are limited mainly to black females with 
SMI. Almost all patients were psychotic, and this study was 
conducted in a tertiary hospital in an urban centre. HIV-
negative patients with less severe or less common mental 
disorders might have been treated in the community. Psychosis 
per se might have been a bias, as the patients with positive 
features (e.g. aggression and hallucinations) might have 
accessed care, and people with negative symptoms might have 
been managed in the community. Patients presenting with 
aggression were more likely to be HIV positive. However, 
these factors may explain why the total length of stay for the 
HIV-positive patients was shorter (Table I), as aggressive or 
unmanageable patients were transferred to another, longer-
term ward. We did not do in-depth interviews and did not use 
validated scales. Therefore, we came to no firm conclusions 
regarding risk behaviour and clinical findings. We did not 
measure other potential confounders, e.g. income, sexual 
behaviour, etc. The socio-demographic characteristics were 
reliably determined. We have confidence in the data, as the 
socio-demographic findings were replicated in the univariate 
and multivariate analysis. Access to health care and criteria 
for admission to hospital are other factors that will affect the 
prevalence of HIV in a hospital setting. An equal proportion 
of HIV-positive and negative patients were psychotic on 
admission. Only patients with SMI were admitted to hospital, 
and access to care was not differential.
Conclusion
Notwithstanding its limitations, this study adds to studies 
of the mentally ill in a generalised epidemic. Our HIV 
seroprevalence finding among those with SMI was larger 
than that of the general population, even after considering 
variation by sex, age and race, which supports our conclusion 
that those with SMI are a vulnerable population and that HIV 
prevention and treatment programmes must be scaled up to 
address their needs. Our study provides empirical data to 
support the recommendations for provider-initiated testing for 
SMI patients.9 More public debate is encouraged on the ethics 
and human rights aspects of PITC in the mentally ill. In South 
Africa, provisions within the Mental Health Care Act allow for 
implementation of PITC.
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